PT3355884T - Fármacos anti-estrogénicos de tetra-hidro-1h-pirido[3,4-b]indol - Google Patents
Fármacos anti-estrogénicos de tetra-hidro-1h-pirido[3,4-b]indolInfo
- Publication number
- PT3355884T PT3355884T PT168526408T PT16852640T PT3355884T PT 3355884 T PT3355884 T PT 3355884T PT 168526408 T PT168526408 T PT 168526408T PT 16852640 T PT16852640 T PT 16852640T PT 3355884 T PT3355884 T PT 3355884T
- Authority
- PT
- Portugal
- Prior art keywords
- pyrido
- tetrahydro
- estrogenic drugs
- indole
- indole anti
- Prior art date
Links
- UIXYIRXTZKEVDP-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-pyrido[3,4-b]indole Chemical compound C1=CC=C2C3CCNCC3=NC2=C1 UIXYIRXTZKEVDP-UHFFFAOYSA-N 0.000 title 1
- 230000001833 anti-estrogenic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000000328 estrogen antagonist Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562235900P | 2015-10-01 | 2015-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3355884T true PT3355884T (pt) | 2021-07-26 |
Family
ID=58427985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT168526408T PT3355884T (pt) | 2015-10-01 | 2016-09-29 | Fármacos anti-estrogénicos de tetra-hidro-1h-pirido[3,4-b]indol |
Country Status (24)
Country | Link |
---|---|
US (5) | US10292971B2 (pt) |
EP (2) | EP3912680A1 (pt) |
JP (3) | JP6776348B2 (pt) |
KR (1) | KR20180071274A (pt) |
CN (2) | CN108366996B (pt) |
AU (3) | AU2016331065B2 (pt) |
BR (2) | BR112018006121B1 (pt) |
CA (1) | CA3000410A1 (pt) |
CL (1) | CL2018000827A1 (pt) |
CY (1) | CY1124669T1 (pt) |
DK (1) | DK3355884T3 (pt) |
ES (1) | ES2881398T3 (pt) |
HR (1) | HRP20211124T1 (pt) |
HU (1) | HUE055321T2 (pt) |
IL (3) | IL310489A (pt) |
LT (1) | LT3355884T (pt) |
MX (2) | MX2018003929A (pt) |
PL (1) | PL3355884T3 (pt) |
PT (1) | PT3355884T (pt) |
RS (1) | RS62133B1 (pt) |
RU (2) | RU2021107754A (pt) |
SI (1) | SI3355884T1 (pt) |
UA (1) | UA122346C2 (pt) |
WO (1) | WO2017059139A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA53837A (fr) | 2014-12-18 | 2021-11-10 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations |
CN108366996B (zh) * | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | 四氢-1H-吡啶[3,4-b]吲哚类抗***药物 |
EP3386500B1 (en) | 2015-12-09 | 2022-09-07 | The Board of Trustees of the University of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
ES2842579T3 (es) * | 2016-02-05 | 2021-07-14 | Inventisbio Llc | Degradadores de los receptores de estrógenos selectivos y sus usos |
US10125135B2 (en) | 2016-04-20 | 2018-11-13 | Astrazeneca Ab | Chemical compounds |
TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
ES2751902T3 (es) | 2016-10-24 | 2020-04-02 | Astrazeneca Ab | Derivado de 6,7,8,9-tetrahidro-3H-pirazolo[4,3-f]isoquinolina útil en el tratamiento del cáncer |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
JP7229162B2 (ja) | 2017-01-06 | 2023-02-27 | ジー1 セラピューティクス, インコーポレイテッド | 癌の治療に対する併用療法 |
AU2018211495B2 (en) | 2017-01-30 | 2020-05-21 | Astrazeneca Ab | Estrogen receptor modulators |
CN110461853A (zh) | 2017-02-10 | 2019-11-15 | G1治疗公司 | 苯并噻吩***受体调节剂 |
CN111770924B (zh) * | 2018-04-04 | 2023-05-09 | 深圳福沃药业有限公司 | 用于治疗乳腺癌的***受体降解剂 |
JP6916969B1 (ja) | 2018-06-21 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 3−((1R,3R)−1−(2,6−ジフルオロ−4−((1−(3−フルオロプロピル)アゼチジン−3−イル)アミノ)フェニル)−3−メチル−1,3,4,9−テトラヒドロ−2H−ピリド[3,4−b]インドール−2−イル)−2,2−ジフルオロプロパン−1−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法 |
EP3902545A4 (en) * | 2018-12-24 | 2022-06-22 | InventisBio Co., Ltd. | NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS |
CA3138197A1 (en) * | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
EP3993785A4 (en) * | 2019-07-07 | 2023-08-02 | Olema Pharmaceuticals, Inc. | ESTROGEN RECEPTOR ANTAGONIST SCHEMES |
EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
CA3169679A1 (en) * | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
WO2022166983A1 (zh) * | 2021-02-08 | 2022-08-11 | 贝达药业股份有限公司 | 杂芳基并哌啶类衍生物及其药物组合物和应用 |
IL309986A (en) * | 2021-07-08 | 2024-03-01 | Olema Pharmaceuticals Inc | Methods for treating diseases related to estrogen receptors |
WO2023091550A1 (en) * | 2021-11-18 | 2023-05-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
WO2023221122A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Salts and solid forms of an estrogen receptor antagonist |
WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
WO2024033513A1 (en) | 2022-08-11 | 2024-02-15 | Diaccurate | Compounds for treating cancer |
WO2024039861A1 (en) | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
WO2024039858A1 (en) | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2024039860A1 (en) | 2022-08-19 | 2024-02-22 | Olema Pharmaceuticals, Inc. | 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer |
WO2024076626A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
WO2024076633A1 (en) * | 2022-10-05 | 2024-04-11 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-mediated disorders |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
ATE247114T1 (de) | 1994-09-12 | 2003-08-15 | Lilly Co Eli | Serotonergische modulatoren |
US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
US6326392B1 (en) | 1997-11-06 | 2001-12-04 | American Home Products Corporation | Anti-estrogen plus progestin containing oral contraceptives |
UA68365C2 (en) | 1997-11-06 | 2004-08-16 | Wyeth Corp | Peroral contraception by combination of anti-estrogen and progestin |
US6479535B1 (en) | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
US6583170B1 (en) | 1998-05-15 | 2003-06-24 | Wyeth | 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
CO5271696A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
CO5271697A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona |
CO5271709A1 (es) | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos |
CO5251465A1 (es) | 2000-01-26 | 2003-02-28 | Pfizer Prod Inc | Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol |
US20020013327A1 (en) | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
WO2002003976A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Combinations of bisphosphonates, estrogenic agents and optionally estrogens |
AR030064A1 (es) | 2000-07-06 | 2003-08-13 | Wyeth Corp | Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos |
EP1990051A1 (en) | 2000-07-06 | 2008-11-12 | Wyeth | Combinations of SSRI and estrogenic agents |
US6358991B2 (en) | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
AU2001271782A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted insole compounds for treating excessive intraocular pressure |
WO2002003977A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Combinations of statins, estrogenic agents and optionally estrogens |
WO2002003986A2 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating breast disorders |
CA2414111A1 (en) | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
AU2001271784A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Therapy for prosthesis-related bone degeneration |
AU2001271781A1 (en) | 2000-07-06 | 2002-01-21 | Wyeth | Use of substituted indole compounds for treating sphincter incontinence |
EP1177787A3 (en) | 2000-07-28 | 2003-09-10 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating cataracts |
EP1318837B1 (en) | 2000-08-11 | 2004-10-06 | Wyeth | Method of treating estrogen receptor positive carcinoma |
EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
IL145838A (en) | 2000-10-16 | 2008-11-03 | Pfizer Prod Inc | Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis |
AU781168B2 (en) | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
EP1417169A2 (en) | 2001-08-11 | 2004-05-12 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
WO2005080380A1 (en) | 2004-02-03 | 2005-09-01 | Eli Lilly And Company | Kinase inhibitors |
AU2005222632B2 (en) * | 2004-03-15 | 2012-02-09 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the inhibition of angiogenesis |
US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
US7767689B2 (en) * | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
CN101146798A (zh) | 2005-01-21 | 2008-03-19 | 詹森药业有限公司 | 用作***受体调节剂的新的杂环苯并[c]色烯衍生物 |
RU58668U1 (ru) | 2006-06-05 | 2006-11-27 | Открытое акционерное общество "Нижегородский машиностроительный завод" | Водогрейный котел |
TWI671297B (zh) | 2009-05-27 | 2019-09-11 | Ptc治療公司 | 治療癌症及非腫瘤病症之方法 |
US20120202801A1 (en) | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
WO2010138695A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
EP3205648A1 (en) | 2010-06-10 | 2017-08-16 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
WO2011159769A2 (en) | 2010-06-17 | 2011-12-22 | Aragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2012084711A1 (en) | 2010-12-24 | 2012-06-28 | Msd Oss B.V. | N-substituted azetidine derivatives |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
JP2015505856A (ja) | 2011-12-16 | 2015-02-26 | オレマ ファーマシューティカルズ インク. | 新規のベンゾピラン化合物、その組成物および使用 |
EP3360875A1 (en) | 2013-05-28 | 2018-08-15 | Astrazeneca AB | Chemical compounds |
MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
SG11201509508YA (en) | 2013-06-19 | 2015-12-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulator and uses thereof |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
RU2745668C2 (ru) * | 2014-10-23 | 2021-03-30 | Ой Эм Ти Джи-Мелтрон Лтд | Осветительное устройство для взрывопожароопасных зон |
KR102106952B1 (ko) * | 2014-10-31 | 2020-05-06 | 카스턴 매뉴팩츄어링 코오포레이숀 | 골프 클럽 헤드의 그루브 및 골프 클럽 헤드의 그루브의 제조 방법 |
US20160175284A1 (en) | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
MA53837A (fr) * | 2014-12-18 | 2021-11-10 | Hoffmann La Roche | Tetrahydro-pyrido[3,4-b]indoles modulateurs des récepteurs des oestrogènes et leurs utilisations |
WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
CN108366996B (zh) | 2015-10-01 | 2021-04-09 | 奥列马制药公司 | 四氢-1H-吡啶[3,4-b]吲哚类抗***药物 |
JP2019521983A (ja) | 2016-06-16 | 2019-08-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロ−ピリド[3,4−b]インドールエストロゲン受容体モジュレーター及びその使用 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
ES2751902T3 (es) | 2016-10-24 | 2020-04-02 | Astrazeneca Ab | Derivado de 6,7,8,9-tetrahidro-3H-pirazolo[4,3-f]isoquinolina útil en el tratamiento del cáncer |
TWI702219B (zh) | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性***受體降解劑 |
AU2019299952B2 (en) | 2018-07-12 | 2022-06-16 | Eli Lilly And Company | Selective estrogen receptor degraders |
-
2016
- 2016-09-29 CN CN201680067297.0A patent/CN108366996B/zh active Active
- 2016-09-29 AU AU2016331065A patent/AU2016331065B2/en active Active
- 2016-09-29 IL IL310489A patent/IL310489A/en unknown
- 2016-09-29 BR BR112018006121-2A patent/BR112018006121B1/pt active IP Right Grant
- 2016-09-29 HU HUE16852640A patent/HUE055321T2/hu unknown
- 2016-09-29 EP EP21164199.8A patent/EP3912680A1/en active Pending
- 2016-09-29 CA CA3000410A patent/CA3000410A1/en active Pending
- 2016-09-29 US US15/764,988 patent/US10292971B2/en active Active
- 2016-09-29 PT PT168526408T patent/PT3355884T/pt unknown
- 2016-09-29 DK DK16852640.8T patent/DK3355884T3/da active
- 2016-09-29 BR BR122023020677-0A patent/BR122023020677A2/pt not_active Application Discontinuation
- 2016-09-29 IL IL286518A patent/IL286518B1/en unknown
- 2016-09-29 KR KR1020187011902A patent/KR20180071274A/ko not_active Application Discontinuation
- 2016-09-29 JP JP2018516524A patent/JP6776348B2/ja active Active
- 2016-09-29 UA UAA201804591A patent/UA122346C2/uk unknown
- 2016-09-29 RU RU2021107754A patent/RU2021107754A/ru unknown
- 2016-09-29 ES ES16852640T patent/ES2881398T3/es active Active
- 2016-09-29 SI SI201631280T patent/SI3355884T1/sl unknown
- 2016-09-29 RU RU2018115696A patent/RU2745742C1/ru active
- 2016-09-29 PL PL16852640T patent/PL3355884T3/pl unknown
- 2016-09-29 EP EP16852640.8A patent/EP3355884B1/en active Active
- 2016-09-29 LT LTEP16852640.8T patent/LT3355884T/lt unknown
- 2016-09-29 MX MX2018003929A patent/MX2018003929A/es unknown
- 2016-09-29 WO PCT/US2016/054549 patent/WO2017059139A1/en active Application Filing
- 2016-09-29 RS RS20210924A patent/RS62133B1/sr unknown
- 2016-09-29 CN CN202110308336.4A patent/CN113248494A/zh active Pending
-
2018
- 2018-03-26 IL IL258363A patent/IL258363B/en unknown
- 2018-03-28 MX MX2021005214A patent/MX2021005214A/es unknown
- 2018-03-29 CL CL2018000827A patent/CL2018000827A1/es unknown
-
2019
- 2019-04-23 US US16/391,686 patent/US10624878B2/en active Active
-
2020
- 2020-04-17 US US16/852,272 patent/US11229630B2/en active Active
- 2020-10-07 JP JP2020169604A patent/JP7277424B2/ja active Active
-
2021
- 2021-07-14 HR HRP20211124TT patent/HRP20211124T1/hr unknown
- 2021-07-22 AU AU2021206861A patent/AU2021206861B2/en active Active
- 2021-07-22 CY CY20211100665T patent/CY1124669T1/el unknown
- 2021-12-06 US US17/542,908 patent/US11672785B2/en active Active
-
2023
- 2023-04-28 AU AU2023202620A patent/AU2023202620A1/en active Pending
- 2023-05-01 US US18/142,068 patent/US20240131013A1/en active Pending
- 2023-05-08 JP JP2023076673A patent/JP2023087106A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258363B (en) | Tetrahydro-h1-pyrido[4,3-b]indole anti-estrogenic drugs | |
SG11202000276YA (en) | Technologies for oligonucleotide preparation | |
HK1243952A1 (zh) | 用於口服的質子結合聚合物 | |
EP3100731A4 (en) | Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof | |
SG11201702298VA (en) | Pharmaceutical preparation | |
ZA201900019B (en) | Pharmaceutical combinations | |
EP3246047A4 (en) | Combination drug | |
PT3157912T (pt) | Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações | |
HK1255014A1 (zh) | 製備取代5,6-二氫-6-苯基苯並[f]異喹啉-2-胺的方法 | |
IL252753B (en) | History of indole and azaindole, their preparation and use | |
GB201703876D0 (en) | Pharmaceutical combinations | |
SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
IL258217A (en) | 2,3,4,5 tetrahydropyridin-6-amine derivatives | |
EP3338805A4 (en) | Drug complex | |
SG10201503820XA (en) | Coloured disinfectant preparation based on bispyridiniumalkane | |
HK1243705A1 (zh) | 吲哚衍生物 | |
PT3023093T (pt) | Preparação medicinal à base de diosmectite | |
GB201504142D0 (en) | Option administration | |
GB201418984D0 (en) | Novel drug conjugates | |
AU2014901289A0 (en) | The Hanger Bag | |
GB201408176D0 (en) | Ligand drug conjugates |